No Detail Found!

Treatment of severe pemphigus vulgaris with rituximab

Author(s)
Fatima Bashir Department of Dermatology, Lahore General Hospital,Lahore,Pakistan
Aitisam Waheed Department of Dermatology, Lahore General Hospital,Lahore,Pakistan
Madiha Sanai Department of Dermatology, Lahore General Hospital,Lahore,Pakistan
Ahmad Kazmi Department of Dermatology, Lahore General Hospital,Lahore,Pakistan
Aneela Asghar Department of Dermatology, Lahore General Hospital,Lahore,Pakistan
Abstract
Pemphigus vulgaris is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-3 and desmoglein-1 located on keratinocytes. Rituximab, a monoclonal anti-CD20 antibody depleting B-cells, offers an effective treatment possibility for therapy-resistant pemphigus vulgaris. Here, we present a case of 20-year-old female who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, mycophenolate mofetil and intravenous immunoglobulins but underwent almost complete remission after rituximab treatment. It was given as two injections of 500mg each at an interval of two weeks in ICU setting.
Publication Details
Page(s) 129-132
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 31, Issue: 1, Year: 2021

Request the full text from PASTIC

Keywords
Desmoglein, Pemphigus vulgaris (PV)
0

Citations

0

Downloads

53

Views